Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Brief Summary: This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Placebo olaparib, Drug: Durvalumab placebo, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Placebo olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: tBRCAm cohort; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Placebo olaparib; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Durvalumab placebo; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Carboplatin+Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort
B: Arm Label: Arm I (paclitaxel and placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo | Arm Label: Arm II (paclitaxel and pazopanib hydrochloride); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Drug: Pazopanib Hydrochloride | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel and placebo), Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and placebo), Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: DRUG; Name: Pazopanib Hydrochloride; Assigned to Arm(s): Arm II (paclitaxel and pazopanib hydrochloride) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (paclitaxel and placebo)
C: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oglufanide disodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: Arm I (closed to accrual 10/10/2008); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Sorafenib Tosylate | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (closed to accrual 10/10/2008), Arm II

Answer: A